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ABSTRACT 
Leino, J., H., 2004. The value of hard gelatin capsules as a rectal dosage form in man using ibuprofen and
metoclopramide hydrochloride as model-drugs.
Dissertationes Biocentri Viikki Universitatis Helsingiensis 16/2004, pp. 47.
There are severeal kinds of clinical situations in the hospital environment that indicate use of
various rectal dosage forms. It is well known that hard gelatin capsules offer a suitable ex tempore
dosage form for use in these cases. The main advantages of using hard gelatin capsules are: their
ease of manufacture enabling strict adjustment of individual dose and low cost production. They
offer also an alternative in serious clinical situations with children, nausea or unconsciuos
patients and patients with gastrointestinal illnesses.
There is very little scientific documentation concerning rectal administration of hard
gelatin capsules. For these reasons the aim of this thesis was to carry out a biopharmaceutical
characterisation of hard gelatin capsules as a rectal dosage form. In the investigations two rectally
well-absorbed model drugs were used: one a weak acid, ibuprofen and the other a weak base,
metochlopramide hydrochloride. Both in vitro and human in vivo tests were utilised. 
It was found that these compounds with different biopharmaceutical characteristics can
be administered adequately in rectally administered hard gelatin capsules. The mean relative
bioavailability of ibuprofen via the rectal route with eight subjects was 99 % (90 % CI 0.81-1.18)
compared with oral administration. It was investigated whether it is possible to modify the drug
release from rectally administered hard gelatin capsules using suitable pharmaceutical excipients
and adjusting their amounts in the capsules. In this study, the adequate immediate-release and
prolonged-release formulations were obtained when ibuprofen and metoclopramide
hydrochloride were used as the model drugs.
In rectal hard gelatin capsules a bioavailability of ibuprofen and metoclopramide
hydrochloride can be achieved which corresponds to that of oral dosage forms. So the rectal
administration route with hard gelatin capsules is not only an alternative, but often also a prime
choice in different clinical situations. However, a clear time lag of 0.5 to 1.5 h was noticed in the
commencement of drug absorption; normally causing a slightly slower absorption phase in the
administration of hard gelatin capsules.
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LIST OF ABBREVIATIONS
AUC area under the concentration-time curve from time 0 to infinity
Cmax maximum concentration
tmax time to peak concentration
t½     elimination half-life
ka absorption rate constant
MRT mean residence time
HPMC hydroxypropyl methylcellulose
K15M the viscosity grade of the HPMC, 15000 mPas measured as 
a 2% aqueous solution at 20 oC
K4M the viscosity grade of the HPMC, 4000 mPas measured as 
a 2% aqueous solution at 20 oC
K100 the viscosity grade of the HPMC, 100 mPas measured as 
a 2% aqueous solution at 20 oC
DSHP disodium hydroxide phosphate
SDHP sodium dihydroxide phosphate
Ph. Eur. European Pharmacopoeia
USP United States Pharmacopoeia
NSAID non-steroidal anti-inflammatory drug
HPLC high-performance liquid chromatography
c.v. coefficient of variation
CI confidence interval
mw. molecular weight
mp. melting point
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1. INTRODUCTION
1.1. Background 
While suppositories are an old form of medication that has been known from the time of
Hippocrates (Abdou 1989), hard gelatin capsules have been used in oral medication since the late
19th century (Jones B. 1987). On the other hand, the origins of gelatin manufacture can be
traced back as far as 4000 B.C. (Jones R. 1987). The first recorded patent for a gelatin capsules
was French Patent 5648, granted in Paris on 25th March 1834 to Dublanc and Mothes. The idea
was quickly acclaimed and its use spread rapidly both inside and outside France. In 1835 capsules
were being manufactured in places as far apart as Berlin and New York (Jones B. 1987). 
In France, capsules were well established by the end of the 19th century. In Britain, the spread
was similar but slower. In the pharmaceutical literature, several attempts were made to
popularise their use, particularly for extemporaneous dispensing. The Chemist and Druggist in 1888
published an article on capsule manufacture (Jones B. 1987). It explained that if it were known
that a dozen capsules could be made in the same time as a dozen suppositories then every
pharmacist would adopt this art. 
In Anglo-Saxon countries, rectal suppository administration accounts for only 1 % to 2 % of all
drugs that are given for their systemic effects. On the other hand, suppositories account for
approximately 15 % to 20 % of all products used in many European and Latin American
Countries. During the last 10 - 20 years or so, several publications on the rectal absorption of
drugs have also appeared in the US and Japan, the world`s two biggest pharmaceutical markets,
where suppositories or other rectal dosage forms had not been previously well accepted from the
cultural and emotional points of view (Hermann 1995). 
Soft gelatin capsules are frequently used for rectal and vaginal application.  A less common rectal
dosage form is the rectal capsule. These are generally similar to soft gelatin capsules except that
they usually have a lubricating coat to aid gliding during administration (Hardy et al. 1987).
Moreover, for example Hannula and co-workers have studied the coating of hard gelatin
capsules with a gliding coat (Hannula 1985, Hannula et al. 1986). Already in the 1960s Wagner  
investigated the effects of dosage form variation on blood levels of the drug, indoxole, and
reported that a soft gelatin capsule (drug dissolved) was equivalent to the emulsion dosage form,
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followed by aqueous suspension, and last was the powder-filled hard gelatin capsule (Wagner et
al. 1966). 
1.2. Physiology and biopharmaceutical characteristics of rectum
The colon consist of the ascending, transverse and descending colons which encircle the small
intestine; the sigmoid colon, which turns medially and downward; the rectum; and the anal canal.
The rectum is about 15-20 cm long, and the anal canal is the last couple of centimetres of the
colon that surrounds the anus. Clinically, however, the terminal end of the colon is usually
referred to as the rectum (Scanlon and Sander 1995). 
Figure 1. Anatomy of the colon (A) and the rectum (B) (The Johns Hopkins Medical Institutions,
Gastroenterology and Hepatology Resource Center, Digestive Disease Library 2004).
The rectum has a good blood supply, and is characterised by absence of villi and a relatively
small surface area (0.02-0.05 ml2). Rectum contains a small volume of viscous fluid (0.5-1.25 ml)
which spread over the surface, and which has a clearly limited buffer capacity. Mostly based on
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these factors, many drugs which are well absorbed orally are poorly absorbed rectally, even when
administered in solution. Even if well absorbed, it is quite common that blood levels may be
more variable after rectal absorption (Wagner 1971, De Boer et al. 1982, Ziegler 1986). Since
only a little fluid is present in the rectum, a greater water solubility is generally required for a
compound to be absorbed rectally as compared with oral absorption. For rabbits, Nishihata et al.
(1984) has shown that the effective rectal fluid volume available to dissolve drugs is only about
0.1 ml. 
The significance of the rectal region, also as an alternative route for administration, has increased
and it is, therefore, of growing interest in drug therapy. It can offer a long residence time and
low luminal peptidase activity; and may have some certain advantages for the absorption of
drugs with reduced permeability across the epithelial barrier and/or increased sensitivity to
enzymatic degradation in the upper part of the gastrointestinal tract (Lennernäs et al. 1995, De
Boer et al. 1992). There are several examples in study reports that the rectal bioavailability of
drugs, even when administered in solution, appears to be drug spesific; examples of suppressed
(Kitazawa et al. 1978, Pappenheimer and Reiss 1987, Madara et al. 1987), similar (Eichelbaum and
Spannbrucker 1977, Sarkar and Karnes 1988, Lee et al. 1993) and even improved (Amidon et al.
1980) bioavailability relative to oral administration can be found.  As an absorption process,
colorectal absorption occurs by passive diffusion through the lipoidal membrane in which
carrier-mediated mechanisms have showed to have no role (Eller et al. 1989).  Since solubilities,
water solubility and lipophilicity, have a reverse relationship, it is apparent that an optimal
balance between these properties is required to achieve optimal absorption (Buur and Bundgaard
1987).
1.2.1. Permeability
The effective permeability of drugs across the intestinal epithelium is influenced by several
physico-chemical and physiological properties and may differ in various intestinal regions (Ho et
al. 1983). Lennernäs and co-workers (1995) have reported that the absorption of water occured
at the lower degree in the rectum compared with other parts of the gastrointestinal tract. They
estimated that it might be explained by a smaller pore radius, tighter epithelium, less fluidity in
the rectal membrane, lower number of pores in the rectal region, and a decreased mucosal
surface area (Davis et al. 1982, Powell 1981, Brasitus and Dudeja 1985, Chadwick et al. 1977). It
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has been proposed that the electrolytes and water are transported transcellularly in the  colon/
rectum, which is different from more high permeable tissue  in which the transport of
electrolytes and water has been assumed to be by the paracellular route (Allen 1983). The tighter
and less fluid rectal epithelium is probably due to a change in the lipid composition, such as
increased cholesterol/phospholipid molar ratio and degree of saturation of fatty acid residues
(Brasitus and Dudeja 1985). Furthermore, Lennernäs with his study group also suggest that an
unstirred water layer is an essential factor since it might be thicker and more coherent in the
colonic-rectal region (Lennernäs et al. 1992) compared with what they and others have found in
the jejunum in man (Levitt et al. 1990, Muranishi 1990). 
The more pronounced effect of the absorption of drugs during an increased convective flow
across the barrier is in agreement with indications that various absorption enhancers seem to be
more effective in the colon/rectum compared with the small intestine (De Boer et al. 1992,
Muranishi 1990). Bile salts such as sodium glycholate seem to bind with calcium ions and sodium
caprate changes the pore size in the tight junctions of membranes. These promoters probably
increase the permeability of membranes to hydrophilic macromolecules via the paracellular
route. Sodium salicylate seems to increase transport by both paracellular and transcellular routes
(Mizuno et al. 1992). Nishihata et al. (1982) investigated the enhancement effect of salicylate on
the rectal absorption of different types of drugs; theophylline as a neutral substance; lidocaine as
a basic material; cefmetazole as acidic and levodopa which exists as a zwitterion in solution.
Absorption of each drug was enhanced,  particularly at pH values were the substances exist
primarly in their ionic form. A requirement for the observed enhancement was that salicylate was
present in the rectal membrane.
1.2.2. Effect of pH 
The rectum as an absorption site has a higher pH (7-8) than that of the gastro-intestinal tract. It
is not a favorable site for the absorption of most of the weak organic acids which have pKa
values lower than the pH of the rectum, because most of the drug molecules exist in an ionized
form in the rectum. If the pH of the drug absorption site in the rectum was temporarily lowered
below the pKa value of the drug, increased rectal absorption of drug would be expected. Yagi
and his study group (1993) found that the mean areas under the plasma concentration-time
curves (AUCs) following the administration of suppositories containing weak acids were larger
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than both those of the suppositories containing bumetanide without weak acids (control) and
those of an orally administered bumetanide suspension in rabbits. Moreover, the pH in the
rectum decreased to between 2-4 for 30 minutes following the administration of the
suppositories containing weak acids, like citric acid or tartaric acid. 
The pH of the rectal fluid is determined by the contents of the rectum, because of the lack on
buffer capacity (Coben and Lieberman 1986). Consequently, the absorption of the drug could be
improved by adding acids or bases to a formulation until the balance of ionized and unionized
forms of the drug is optimal.  In this way it could be possible to improve the solubility of the
drug in the rectal fluid and at the same time ensure sufficient permeability. On the other hand, it
has been determined that under the conditions met in the study of Crommelin et al (1979): the
rectum is able to secrete neutralizing agents when the luminal pH deviates from the physiological
pH. The degree of the secretion depends on the magnitude of the deviation. In general, the
dissociation reaction of a drug is an equilibrium reaction. Thus, if some of the undissociated
form of a drug is eliminated from the system, new undissociated drug will be formed to
compensate (Ritschel 1992). Consequently, the proportion of the undissociated drug need be
only 1-2% in order to be absorbed. 
1.2.3. Question of first-pass metabolism
Rectal administration has been recommended as a non-invasive alternative for drugs which are
largely metabolized by the liver or excreted in the bile and for those subject to degradation in the
gastrointestinal tract (Jonkman et al. 1979). Also, drug administration in the lower part of the
rectum is useful as an almost non-hepatic route for high-clearance drugs such as lidocaine,
propranolol, nitroglycerin and certain narcotic analgesics like morphine (De Boer et al. 1979). 
Although partial avoidance of first-pass elimination may in principle occur in the lower part of
the rectum (De Boer et al. 1979), many human rectal bioavailability studies have clearly
demonstrated presystemic eliminination, usually equal to (Jonkman et al. 1979, Westerling et al.
1982, Moolenaar et al. 1979A, 1981, 1983) but sometimes even exceeding that (Moolenaar et al.
1978, 1979B) after oral dosing. In this respect it should be emphasized that rectally administered
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fluids do not remain in the lower part of the human rectum, but they spread upward to a region
where veins draining into the portal circulation predominate (Moolenaar and Schoonen 1980). 
The possible liver-based first-pass metabolism in the rectum is assumed to happen mainly in a
two different ways. When the drug is absorbed in the inferior or middle rectal veins, it probably
reaches the superior rectal veins by way of the numerous connections (anastomoses) between
them. Another possibility is that the dosage form quickly reaches the higher parts of the rectum
and thus the drug is directly absorbed into the superior rectal veins  (Jonkman et al. 1979).
  
To test the hypothesis that first-pass metabolism is at least partially avoided when a drug is given
rectally, since part of the rectal drainage is directly into the vena cava, de Boer and co-workers
(1982) administered lidocaine to six volunteers intravenously, perorally (gelatin capsules) and
rectally (aqueous solution) in a cross-over design. Corrected for dose size differences, the oral
bioavailability was 31 ± 11% (S.D.) and the rectal bioavailability was 63 ± 23% (S.D.). In a
follow-up study (De Boer et al. 1982b) in the same six subjects the mean oral bioavailability was
27% and the rectal bioavailability 67%, indicating good agreement between the individual data of
the two studies. 
Many drugs are metabolized at the absorption site, in the colorectal area, in many cases by the
enteral bacteria (e.q. atropine, steroids, polypeptide drugs, indomethacin, sulphasalazine, l-dopa,)
(Fara 1985). Furthermore, there are peptidase enzymes in the membrane of the rectum which
metabolize proteins and peptides, so the rectum is not only the physical barrier but also the
metabolic barrier (De Boer et al. 1990). 
1.2.3.1. Existence of efflux proteins
Increasing interest is focused on the role of the efflux proteins.in scientific literature during the
last decade. These proteins like P-glycoprotein and other multidrug resistance proteins form a
group of ATP-binding cassette transporters that act as energy-dependent efflux pumps
transporting a wide variety of low molecular weight compounds out of cells. Transporters can
recognize and efflux numerous substrates with varied chemical structures, including many
anticancer drugs. While the molecular mechanisms underlying the broad substrate spesificity of
efflux proteins are generally unknown; it appears that in the intestinal tract epithelia the drug is
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effluxed by flipping the drug from the inner to the outer leaflet of the bilayer membrane
(Kondratov et al. 2001). This model is consistent with the ability of compounds to penetrate lipid
and the common denominator is that the P-glycoprotein substrates are hydrophobic and
amphipathic in nature. 
A wide variety of drugs suffer from incomplete, variable and non-linear absorption. Similarly, at
the blood-brain barrier a range of drugs have limited brain penetration due to
P-glycoprotein-mediated-efflux, which can limit therapeutic effectiveness of CNS agents (Ayrton
and Morgan 2001). For absorption, a clear role has emerged for P-glycoprotein in limiting
permeability across the gastrointestinal tract. The drugs that can be effluxed from the cell by
glycoprotein include e.g. cyclosporin A, digoxin, erythromycin, antibiotics, cimetidine.
Inhibition of P-glycoprotein improves intestinal absorption and tissue distribution while
reducing the metabolism of the substrate and its elimination (Varma et al. 2003). P-glycoprotein
can often be the mechanism for significant pharmacokinetic drug interactions when two or more
drugs are competing for the P-glycoprotein transport site (Johnson 2002). 
Together with drug-metabolising enzymes, transmembrane transporters are important
determinants of drug metabolism and clearance by the liver (Faber et al. 2003). An overwhelming
proportion of clinically relevant drug interactions where the intestine has been implicated as a
major contributor to first-pass metabolism involves drugs that undergo cytochrome P450(CYP)
3A4-mediated biotransformation and are substrates for the efflux transporter P-glycoprotein
(Doberty and Charman 2002).  These two integrated and complex systems exist, among other
places, in the tips of the villi of the intestinal tract: P-glycoprotein is expressed in a variety of
normal human tissues including the liver, brain, adrenal gland, kidney and intestinal tract
epithelia.  Thus, P-glycoprotein might have a potential role in transformation of the oral
bioavailability of many clinically important drugs, it is obviously of no biophamaceutical
importance in rectum because of the absense of the villi. Most of the study reports concerning
the efflux proteins focus on the upper parts of the intestinal tract. 
1.3. Rectal drug administration
Over a long period of time the rectal route was used only for the administration of local
anasthetics, anti-haemorrhoidal, vermifugal and laxative agents. Now the majority of natural and
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synthetic drugs are also formulated in the different kinds of rectal dosage forms to produce a
systemic effect (Hermann 1995). Absorption following rectal administration is often said to be
unreliable, but this route can be adequate to patients who are vomiting or nauseous, or who are
unable to take medication by mouth (e.g. postoperatively). The rectal dosage forms are used to
administer diazepam to children who are in status epilepticus in whom it is difficult to establish
intravenous access. Study reports concerning the rectal administration of diazepam have shown
that,  being a lipophilic drug, it is better absorbed from hydrophilic than lipophlic suppositories
(Marvola et al. 1981, Redgon et al. 1994). Often, though, the reasons for avoiding the rectal route
appear to be more cultural than pharmacological.  
Many reserchers have concentrated their efforts in rectal drug absorption on those drugs which
currently must be injected parenterally to provide effective therapy. Those drugs may be divided
into two categories: antibiotics (e.g. streptomycin, cefazolin) and polypeptides (heparin,
interferon, insulin, gastrin) (Nishihata et al. 1982, Caldwell et al. 1984, Muranishi 1984, Ritschel
and Ritschel 1984, Davis et al. 1985, Beskid et al. 1988, Bahia and Giuedes 1991, De Muynck et al.
1994, Nishihata et al. 1984b). The suppository or some other rectal dosage form may be useful as
a sustained-release formulation for the long-term treatment of chronic diseases like essential
hypertension, asthma, diabetes, AIDS, anaemia, etc. (Kurosawa 1985, Kawaguchi et al. 1991,
Morgan et al. 1992, Reynolds 1993, Hsyu et al. 1994). Furthermore, there is a growing interest in
the possibility of rectal administration in the treatment of post-operative pain and malignant pain
(Moolenaar et al. 1984, Leow et al. 1992, Saruki et al. 1992, Koja et al. 1994). 
Storey and Trumble (1992) have investigated the rectal absorption of carbamazepine and
doxepin when the drugs were administered in hard gelatine capsules. The study was established,
because many cancer patients, who needed the medication, were not able to take it orally and
there were no injectable products on the market at that time. As a result, all patients benefited
from the rectal administration of hard gelatine capsules. The general status of the patients, who
have had pains and attacks, was notably improved.
1.3.1.  Advantages of using a hard gelatin capsule as a rectal dosage form
It is generally known that hard gelatin capsules, either manufactured ex tempore or commercial
brands, are used in some clinical cases in hospitals, although the commercial ones, unlike for
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example some soft gelatin capsules, are not officially accepted for rectal use. There are many
clinical applications or situations where the use of rectal dosage forms is preferable; as can be
seen from the following detailed arguments concerning hard gelatin capsules administered
rectally: 
1. Can be manufactured ex tempore in the hospital and/or retail pharmacies
2. Enable strict individual adjustment of the dose; better than e.g. suppositories        
 and soft gelatin capsules
3. Simple and low-cost production
4. A relatively great variation of drugs can be employed; from antibiotics and            
        NSAIDs to polypeptides
5.       Possibility to avoid, at least partially, first-pass metabolism; especially with             
 high-clearance drugs
      6. Offer an alternative way in different and/or serious clinical situations with            
      children, nauseous or unconsciuos patients, aged people, patients with certain       
    gastrointestinal illnesses, etc.
       7. As a dosage form, relative easy to formulate; presumably when immediate or        
     slow release profile is required 
      8.     Possible to employ acid labile, stomach-irritating or bad tasting drugs
 9.     Food intake does not have a direct effect on the drug administration; unlike in      
      oral medication
10.  Offer a relatively steady environment and long residence time for drugs to be       
    absorbed
   11. Replace in some cases the use of other administration routes, e.g. 
 parenteral dosage forms 
According to the pharmaceutical literature, one of the main reasons for the unpopularity of  
rectal dosage forms, beside the incovenience, is the lack of reliable in vitro/in vivo correlation in
the evaluation of their therapeutic effectiveness (Abdou 1989). It is also possible that factors
which are not directly dependent on the dosage from; like unfamiliar and partly difficult
administration technique, compliance and spesific character of the absorption region, can cause
problems in rectal administration of hard gelatin capsules.  Our laboratory group made
experiments on immediate relese and sustained release capsule formulations containing
ibuprofen as a model drug and HPMC of different viscosities as diluents (Ojantakanen et al.
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1993).  Furthermore, it has been shown that e.g. sustained release hard gelatin capsules, for oral
or rectal administration, are relatively uncomplicated to produce by adding suitable hydrophilic
polymer to the formulation (Ojantakanen et al. 1993, Marvola et al. 1991, Ojantakanen 1992,
Efentakis and Vlachou 2000). 
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2. AIMS OF THE STUDY
As shown in the review of literature, there is very little scientific documentation concerning
rectal administration of hard gelatin capsules. However, some special indications exist where
administration of hard gelatin capsules via the rectal route would be justified. For these reasons
the overall aim of the present study was to carry out a biopharmaceutical characterisation of hard
gelatin capsules as a rectal dosage form. In the investigations two rectally well absorbable model
drugs were used: one a weak acid (ibuprofen), the other a weak base (metochlopramide
hydrochloride). Both in vitro and human in vivo tests were utilised. The detailed aims of the study
were:
1. To study whether training in rectal administration (I) or dipping of        
        capsules into liquid paraffin (I, II, III) or coating them with hard fat (III,   
      IV) would affect drug bioavailability from the capsule or facilitate drug     
         administration. 
2.   To determine the relative bioavailability of rectally administered capsules  
           compared with that after oral dosing of the corresponding capsule (I).
3. To determine the relative bioavailability of the rectal capsule compared 
with a corresponding soft gelatin capsule (III) or commercial
suppositories (III, IV).
4.     To study the effect of the type of diluent (water-soluble, water-insoluble
 or gel-forming agent) on the bioavailability of the model drugs (I-IV).
5.   To test whether long-acting rectal formulations could be developed using
        different grades of hydrophilic polymers as a diluent (II, IV).
6. To study whether it would be possible to enhance the bioavailability of
 the model drug by regulating the ionisation degree of the model drug
 with pH-regulating inorganic salts as additives (III). 
7. To evaluate whether it would be possible to predict the in vivo behaviour
 of the formulations based on the results gained in the in vitro dissolution    
              tests (I-IV).
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3. MATERIALS AND METHODS
3.1. Model drugs 
3.1.1. Ibuprofen
Ibuprofen (Ph. Eur., Industrial Chemica Prodotti, Italy, particle size < 0.3 mm) was used as a
model drug in hard gelatin capsules (I, II and III). Ibuprofen (mw. 206.3) is a non-steroidal
propionic acid derivative with anti-inflammatory, analgesic and antipyretic properties. Its
pharmacological mechanism is based on inhibition of cyclo-oxigenase thus preventing
prostanoid synthesis.  
Figure 2. Chemical structure of ibuprofen.
Ibuprofen is regarded as a representative of drug that is well absorbed throughout the
gastrointestinal tract (Wilson et al. 1989, Van Hoogdalem et al. 1991). It is also widely used and
safe (Van Hoogdalem et al.1991.).  Ibuprofen is a weak acid with a pKa of 5.3 and it is sparingly
soluble in water (Herzfeldt and Kummel 1983). Its solubility change in the physiological pH
range, as reflected by the volume required to dissolve a dose, ranges from 12 l to 100 ml as the
pH increases from 1 to 7.4  (Corrigan 1997). After an oral dose, ibuprofen enters the systemic
circulation mainly in its unchanged form (Mills et al. 1973).  It has a short elimination half-life of
only about two-hours and the therapeutic plasma drug concentration is 5 to 50 mg/l.  The
pharmacokinetics of ibuprofen is non-linear, thus, the bioavailability of ibuprofen does not
increase correspondingly with the dose (Lockwood et al. 1983). This is explained by the intense
and non-linear protein binding of ibuprofen, in vitro over 99 %. The HPLC technique for
determination of ibuprofen from plasma samples is fairly easy (3.4.2.). 
12
3.1.2. Metoclopramide hydrochloride
Metoclopramide hydrochloride (particle side < 300 um, BP 93, Dolder, Switzerland) was used as
a model drug in hard gelatin capsules, reported in paper IV. Metoclopramide (mw. 300.0) is the
methoxychlorinated derivative of procainamide (Buss et al. 1995) and further metoclopramide
hydrochloride is a water-soluble salt form of the lipid-soluble metoclopramide. The
pharmacological effects of the drug in man relate to at least two actions: a dopamine receptor-
blocking effect (Pinder et al. 1976) and an effect on cholinergic mechanisms possibly increasing
acetylcholine release (Hay 1977). Metoclopramide is a widely used drug in the treatment of
vomiting and disorders of gastrointestinal motility. It is one of the least toxic antiemetics and its
commonest side effect is drownsiness. Metoclopramide is rapidly and well absorbed in the
gastrointestinal tract (Bateman1983) and in man it undergoes variable first-pass metabolism (oral
bioavailability 32 to 100%). 
3. Figure. Chemical structure of metoclopramide.
A single dose of 20 mg metoclopramide per os produces peak plasma concentration of approx. 40
ng/ml within 1 hour with interindividual variation due to first-pass hepatic metabolism. The
usual therapeutic dosage of metoclopramide in adults is 10 mg four times daily. The elimination
half-life is 2.6 to 5 hours in healthy volunteers (Harrington et al. 1983). Single-dose studies have
suggested that the elimination of metoclopramide is dose-dependent in man after both i.v.
(Graffner et al. 1979) and oral administration (Bateman et al. 1980). The half-life, for example,
after a single 10 mg oral dose was 3.28 ± 1.32 hours and after a 20 mg oral dose 5.29 ± 1.61
hours (p<0.05). The bioavailability of metoclopramide was found to be significantly correlated
to the ratio of free/conjugated metoclopramide in urine. Since metoclopramide N-4 sulphate is
the major metabolite in man, these data suggest that sulphate conjugation (phase II) at the first
pass through the gut wall or liver is the factor governing the bioavailability (Bateman et al. 1980). 
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3.2. Pharmaceutical excipients 
3.2.1. Gel-forming additives
Hydroxypropylmethylcellulose and polycarbophil were used to control the drug release from the
hard gelatin capsules. HPMC is widely used in peroral controlled-release dosage forms (Smal et
al. 1994; Sirkiä et al. 1994 b, Halsas et al. 1998).  Three viscosity grades of HPMC (MethocelR
K100, K4000; Dow Chemical, United Kingdom and K15M; Colorcon, United States) were used
in the study (I, II). The viscosity grade of the polymer depends on the number of substituents in
the structure of the polymer and the length of the cellulose chain.The viscosities of the HPMCs
were 100, 4000 and 15000 mPas measured as a 2% aqueous solution at 20 oC. 
Polycarbophil (NoveonR AA-1, BF Goodrich company, United States) was used in studies II and
IV. It is a synthetic hydrophilic resin of the polyacrylic acid type, a co-polymer of acrylic acid
loosely cross-linked with divinyl glycol able to contain a considerable amount of water without
dissolving. Carbopol resins are used  e.g. in controlled-release dosage forms and to bioadhere in
buccal, vaginal, opthalmic, intestinal, nasal, vaginal and rectal applications. Carbopol
homopolymer resins are called in pharmaceutical literature as Carbomer, carboxyvinyl polymer,
carboboxy polymethylene and polyacrylic acid. The NoveonR series of carbopol resins are
generically known as polycarbophil (Product Information, BF Goodrich). Polycarbophil is used
to control drug release from oral formulations as well as to improve the rectal bioavailability of
model drugs in both humans (Hosny E. 1988.) and dogs (Hosny and Robinson 1991, Hosny and
Al-Angary 1995; Hosny et al. 1995). 
 
3.2.2. Other excipients 
Disodium hydrogen phosphate (DSHP; Friedel-De Haen AG, Germany) and sodium
dihydrogen phosphate (SDHP; Friedel-De Haen, Germany) were used in the formulations
according to the proportions of the phosphate buffer solution 7.5 in Ph. Eur. (III). Sodium
phosphates are used as buffering agents in pharmaceutical technology. 
Lactose  (I, II, III, IV; Der Melkinindustrie Veghel, the Netherlands) and dicalcium phosphate (I;
Oriola Oy, Finland) were used in the hard gelatin capsules as diluents. They are commonly used
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in tablet and capsule formulations. Liquid Paraffin (I, II, III; Fina Europe, Belgium) was used to
adjust the administration of the capsules. The Hard Fat, adeps solidus, (III, IV; WitepsolR W45,
Condea Chemie GmbH, Germany) was used for coating the capsules in order to facilitate the
insertion. 
3.3. STUDY FORMULATIONS
Three sizes of hard gelatin capsules were used in the formulations. Size 0: Studies I, II (Posilok,
Elanco) and IV (Coni-Snap, Capsugel) and sizes 1 and 00: Study III (Coni-Snap, Capsugel). The
amounts of the model drugs and the compositions of the products are presented in Table I. 
Table I.
Model Drug Study I Study II
a b c d e f g h i j k
Ibuprofen 200 200 200 200 200 200 200 200 200 200 200
Excipient
HPMC K15M - - - 136 - - - - - - -
HPMC K4M - - - - - - 101 - - - -
HPMC K100 - - - - - 103 - - - - -
Polycarbophil - - - - - - - 68.8 32.9 15.8 5.1
Lactose - 195 - - 195 - - - 96.5 89.3 96.9
Dicalcium phosp. - - 178 - - - - - - - -
100/0 75/25 85/15 95/5
Capsule size 0 0 0 0 0 0 0 0 0 0 0
Model Drug Study III Study  IV
l m n o p q r
Ibuprofen 200 400 400 400 400 - -
Metoclopramide HCL - - - - - 20 20
resp. metoclopramide
Excipient
DSHP - - - 28 47 - -
SDHP - - - 2 3 - -
Polycarbophil - - - - - - 19
Lactose 71 100 65 29 25 391 356
Capsule size 1 00 00 00 00 0 0
The necessary amounts of the model drugs were weighed in a measuring cylinder and the
excipients added in such a way as to obtain sufficients material for a batch of 100 capsules. The
total volume was 50 ml for size 1 capsules (III), 68 ml for size 0 capsules (I, II, IV) and 95 ml for
size 00 capsules (III). The powders were mixed manually, and the capsule bodies were filled
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using a Feton apparatus. Some of the capsules were dipped in liquid paraffin before
administration (I, II) or their were coated by dipping them into melted hard fat (mp. 35 oC) using
tweezers (III, IV).
Three commercial products were used as reference formulations: a suppository product (BuranaR
500 mg, Orion, Finland) and a soft gelatine capsule product (Burana-CapsR 400 mg, Orion,
Finland) for the studies concerning ibuprofen (III) and a suppository product (MetopramR 20
mg, Leiras, Finland) for metoclopramide (IV).
3.4. Dissolution studies
A number of in vitro dissolution techniques for determination of the dissolution rate of drug
substances from suppositories and other rectal dosage forms are described in the literature. The
techniques can be divided roughly into two groups; those not using membranes and those that
do use membranes (Bornshein et al. 1985).
In the studies reported here, the dissolution of the model drugs was studied using the basket
method described in USP 22-24. The dissolution medium was a phosphate buffer, pH 7.2 (I, II,
III) for the ibuprofen formulations, except pure water for the ibuprofen formulations contained
phosphate-buffers (III). Water was also used as the medium for the metoclopramide
hydrochloride formulations (IV). The speed of rotation was 150 rpm (I, II, III) or 50 rpm (IV).
The dissolution apparatus (Sotax AT 6, Sotax AG, Switzerland) was connected to a peristaltic
pump (Watson-Marlow 503S, Smith&Nephew Watson-Marlow, United Kingdom) and to a
flow-through spectrophotometer (Ultrospec II, LKB Biochrom Ltd., United Kingdom). The
absorbances of the dissolution medium in 2-mm flow-through cells at 221 nm for ibuprofen (I,
II, III) and at 275 nm for metoclopramide (IV) were controlled and recorded at the regular
intervals by a computer dissolution system (TDS, LKB Biochrom Ltd., United Kingdom; I, II,
III, IV). The amount of model drug released was measured from parallel in six samples. 
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3.5. Bioavailability studies
3.5.1. Experimental procedure
Six to eight healthy volunteers (age 19 to 40 years and weight 50 to 85 kg), who had given their
written consent, participated in randomized, cross-over, single-dose studies. The studies were
carried out in accordance with the provisions of the Declaration of Helsinki (World Medical
Assembly, 1964) and its subsequent revisions. The volunteers were informed about the possible
risks and side-effects of the drugs.  The subjects trained in rectal administration before the study
using exercise capsules containing only lactose as a diluent. During the study, side effect forms
were filled out and collected. The study protocol was approved by the Ethics Committee of the
University Pharmacy (Helsinki). The National Agency for Medicines (Finland) was duly notified.
Drug administration took place at 8 a.m. (Studies I, II) after overnight fast for at least 10 hours
and afterwards in Studies III and IV, breakfast (7 a.m.) was permitted to facilitate and enable the
normal bowel movement. A standard lunch was served 4 hours after drug administration. The
wash-out period was at least one week. Blood samples were collected from an antecubital vein
into heparinized tubes before drug administration and then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (I, III) and
24 hours (II, IV) thereafter. Plasma was separated approximately 0.5 hour after collection by
centrifugation (3000 g for 10 min) and stored at - 20 oC until analysis.
3.5.2. Plasma assay 
The model drug plasma concentration was determined by means of high-performance liquid
chromatography using a slight modification of the method of Avgerinos and Hutt (1986) for
ibuprofen (I, II, III) and a slight modification of the method of Buss et al. (1990) for
metoclopramide (IV). Each plasma sample was analysed in duplicate and the mean value was
recorded.
The system was equipped with a pump and its controlling unit (Waters, Millipore, United States),
a sample processor (Waters, Millipore, United States), a Waters Model 486 Tunable Absorbance
Detector operating at 221 nm for the ibuprofen studies (I, II, III) and at 275 nm for the
metoclopramide study (IV), and a Waters workstation. Sample separation was carried out in a
17
Lichrosorb RP-18 reverse phase column in the ibuprofen studies and a cyano column (Hibar
Lichrosorb CN) in the metocloparmide study (IV). The isocratic mobile phase was acetonitrile
and 0.1 M sodium acetate (35/65, pH 6.2, flow rate 2 ml/min) for the ibuprofen studies (I, II,
III) and acetonitrile and 0.02 M potassium dihydrogen phosphate (40/60, pH 3.0, flow rate 1
ml/min) for the metoclopramide study (IV). 
All the standard curves were found to be linear over the concentration ranges. The linear
coefficient of determination were 0.998 or higher. The accuracy and precision of the method
were investigated as recommended by Shah et al. (1992) by analysing six plasma concentrations
1, 20, 40 mg/l (I, II, III) and 5, 20, 80 ng/ml (IV). The detailed mean values are given in the
original papers. The limit of quantitation was estimated to be 1 mg/l (I, II, III) and 5 ng/ml (IV).
No interfering peaks were observed in the plasma blanks.
3.5.3. Pharmacokinetic parameters
In all the absorption studies the following pharmacokinetic parameters were assessed (Siphar,
Simed, France): maximum plasma concentration (Cmax), time to peak concentration (t max), area
under the concentration-time curve (AUC), mean residence time (MRT), apparent elimination
half-life (t1/2; only in Study IV) and lag-time (tlag; only in Study III). The rate of absorption was
evaluated also using the ratio Cmax/AUC. For AUC values, 90%-confidence intervals with
logarithmic transformation were calculated. The data were analysed using Student` s t-test or
paired t-test; tmax-values were analysed with Wilcoxon`s matched-pairs rank test.
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4. RESULTS AND DISCUSSION
4.1. Dissolution studies
Traditionally there are two classic cases in which release is limiting the absorption: these are
immediate-release dosage forms containing drugs that are poorly soluble and controlled-release
dosage forms (Dressman 2000). The USP dissolution method used was not only carried out to
control the batch quality, but predominantly to investigate drug release mechanism with robust
drug release profiles and to get supportive data for interpretation of bioavailability studies. It can
be mentioned that three kinds of study formulations were tested in the dissolution studies:
formulations containing rapidly dissolving diluents like water-soluble lactose (I, II, III, IV) or
sparingly water-soluble dicalcium phosphate (I),  or gel-forming diluents like
hydroxypropylmethylcellulose (I, II) and polycarbophil (II, IV) and, finally, sodium phosphates
as pH-regulative agents.
The lactose-based capsules were used as a model for immediate release formulation, but also as
a reference for the controlled-release formulations in the in vitro and in vivo studies. The release of
ibuprofen from the lactose capsules occurred completely in 10 minutes in all studies where the
medium pH 7.2 was used (I, II). The dissolution profile of ibuprofen was similar when plain
ibuprofen or dicalcium phosphate as a diluent was used in the capsules. These results are in
accordance with the findings with tolfenamic acid studied by Eerikäinen and co-workers (1989)
and with ibuprofen studied by Ojantakanen et al. (1990). The rate-limiting step in the dissolution
process was the rupture of the capsule shell and penetration of water into the capsule. The
dissolution of ibuprofen from lactose-based capsules was also studied in the medium containing
pure water (III). This was the medium used for the ibuprofen capsules containing sodium
phosphates as diluents where lactose-based capsules were employed as a reference product. The
dissolution of ibuprofen from lactose-based capsules in pure water was still under 20% after 4
hours (III, Fig. 1.). This was clearly due to the low aqueous solubility of ibuprofen. 
The dissolution of the water-soluble hydrochloride salt-form of metoclopramide in pure water
was relative fast, more than 80% was released at 10 minutes (IV, Fig. 1.). Thus, the dissolution of
metoclopramide hydrochloride occured at a slightly slower rate than the dissolution of sparingly
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water-soluble ibuprofen in pH 7.2 phosphate buffer from lactose-based ibuprofen capsules but
was, however, fair fast-releasing, reflecting the good immediate-release character in vivo.
Gel-forming excipients such as hydrophilic polymers hydrate on contact with water form a
gelatinous clump over and within the powder bed (drug/diluent) from which the drug is released
by diffusion and erosion mechanisms. This normally produces a slowly-disintegrating powder
bed resulting in a sustained-release profile for the drug. 
Three different viscosity grades of hydroxypropyl methylcellulose were studied (I, II): HPMC
K100, K4M and K15M. Various studies have reported (Ojantakanen et al. 1992 and 1993, Smal
et al., 1994, Ford et al. 1985a and 1985b) that the in vitro release rate of the drug from HPMC
(and NaCMC-based) capsules is depended on the molecular weight (viscosity grade) of the
polymer diluent and is further greatly affected by the drug/polymer ratio in the formulation. The
amounts of HPMC used in capsules reported in this thesis were about the same as the amounts
used by Ojantakanen et al. (1993) thus describing the same drug/polymer ratio. The K15M
formulation liberated ibuprofen from the capsules relative slowly, with only 75% of ibuprofen
being dissolved at 24 hours (I). Formulations based on K100 and K4M with lower viscosity
characteristics liberated ibuprofen considerably faster: 100% of ibuprofen was dissolved in 4
hours with the K100-based capsules and in 16 hours with the K4M-based capsules (II, fig. 1.). It
was noted that the tight mass was formed in the capsules when the viscosity of the HPMC rose.
The K15M and K4M capsule formulations behaved as prolonged-release capsule formulations.
The dissolution behaviour was in agreement with the results of a study by Ojantakanen (1992). 
The dissolution of ibuprofen from capsules containing 100% of another type of gel-forming
agent, polycarbophil (Noveon AA-1), was still incomplete after 24 hours. When the amount of
polycarbophil in the capsules was decreased, the liberation of ibuprofen from the capsule mass
and thereafter the dissolution of ibuprofen was accelerated. The ibuprofen was completely  
dissolved in two hours when the polycarbophil portion of the adjuvant mixture was 15%.
Further when the polycarbophil portion was decreased to 5%, the ibuprofen was dissolved in 75
minutes (II, Fig. 1.). Thus the dissolution results showed that even a small amont of
polycarbophil in the diluent mass retarded the dissolution of ibuprofen. These findings are in
accordance with the results of the study by Hosny (1992) where propranolol hydrochloride and
indomethacin were almost completely released in two hours or more quickly when the amount
of polycarbophil in the matrix tablets decreased from 20 to 5%.
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The dissolution of water-soluble metoclopramide hydrochloride from the capsules containing
5% of polycarbophil was biphasic (IV). Most of the drug (80 %) was released in 30 minutes and
then the rate apparently decreased so that dissolution was still incomplete after 6 hours (IV, Fig.
1.). The terminal part of the dissolution curve was obviously due to the hydration effect of the
polycarbophil prolonging the drug release. This kind of dissolution behaviour was not observed
in our previous studies with ibuprofen. In conclusion, however, it was clearly noted that using
different gel-forming excipients as diluents in capsules the release-rate of drugs, in this case a  
weak acid, ibuprofen, and a salt-form base, metoclopramide hydrochloride, can be modified and
even controlled in vitro. 
There are, at least in theory, three cases in which pH regulators or antacids may enhance the
absorption of an acidic drug: enhancing the disintegration rate of the dosage form, enhancing the
dissolution rate of the dosage form or, finally, enhancing the gastric emptying rate (Hannula et al.
1991). Two different sodium phosphate-based formulations were tested (III). The capsules
contained 0 mg, 30 mg or 50 mg of a sodium phosphate mixture according to Ph. Eur. 7.5
phosphate buffer solution. Thus the ratio of disodium hydrogen phosphate to sodium
dihydrogen phosphate was 14:1. The medium in the dissolution test was water because of the
strong buffer capacity of medium pH 7.2 (Ph. Eur.). From the lactose-based hard gelatin
capsules containing 0% of sodium phosphates, 17% of the ibuprofen dissolved in 4 hours in the
water medium. Phosphates caused an increase of dissolved drug: from the formulation
containing 30 mg of phosphates 27% of the ibuprofen dissolved in 4 hours and from the one
with 50 mg of phosphates 31% of the ibuporfen dissolved in the same time (III, Fig. 1.).
Takubo et al. (1973) reported that addition of buffer reagents to the suppository is one way of  
enhancing the dissolution and absorption rates of sulfonamides and possibly other sparingly
soluble drugs. Furthermore, Hannula et al. (1991) reported that the absorption of ibuprofen from
sodium bicarbonate-based hard gelatin capsules was found to be significantly faster than that
from capsules containing either lactose or dicalcium phosphate as diluent. The main reason for
this was assumed to be the rapid in vivo disintegration of the sodium bicarbonate capsules.
However, it may also be due to the enhanced dissolution of ibuprofen resulting from the rise of
pH in the stomach. It is concluded that for rapid absorption of ibuprofen from capsules the
water solubility and carbon dioxide formation of the additive are the most important factors. An
increase in pH leading to an enhanced dissolution rate may potentiate this effect (Hannula et al.
1991). The dissolution findings reported in this thesis concerning sodium phosphates as
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pH-regulators showed that they also act in such a way as to increase the dissolution rate of the
acidic drug, ibuprofen. 
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4.2. Bioavailability studies
Bioavailability studies were performed in four phases, which are reported correspondingly in
Studies I, II, III and IV. These studies with healthy volunteers were based on the in vitro studies
carried out before the bioavailability study in question. Study design and the procedure including
the plasma assay were always the same in the studies.
4.2.1. Evaluation as a rectal dosage form (I)
The primary aim for the bioavailability studies reported in this thesis was to evaluate the value of
hard gelatin capsules in rectal administration in man. Ibuprofen was chosen as the model drug,
because it is a safe and widely used drug which is known to be absorbed well throughout the
gastrointestinal tract, including the colon (Parr et al. 1987, Wilson et al. 1989). In the first step
two common diluents were selected as diluents in the capsules, i.e. water-soluble lactose and
sparingly water-soluble dicalcium phosphate (I, Fig. 1.). The ibuprofen levels in plasma were just
on the therapeutic level in most volunteers (over 10 mg/l), but the amounts of absorbed drug
were comparatively low with proportionately large indivual variations (I, Fig 2.). On three
occasions with lactose-based capsules and two with dicalcium phosphate based capsules, no drug
was detectable during the 12-hour test period. The volunteers with no observed ibuprofen levels  
reported difficulties in the application. The difficulties could be caused by normal bowel
movement or, for example, sticking of the capsule to the outer sphincter of the rectum. When
these capsules were compared with the similar capsules given orally (Ojantakanen 1990), it was
noticed that the bioavailability of the rectally administered capsules was only 55-60% of that with
oral capsules. These findings was thought to be due to the difficult administration technique. 
On the basis of these results our aim was next to investigate whether it is possible to improve the
bioavalability of ibuprofen by training in the administration technicue and also by facilitating the
insertion of the capsules. The capsules were dipped into liquid paraffin before application. The
subjects also practised the administration technique using pure lactose capsules before
participating in the bioavailability studies. A bioavailability test was then carried out with capsules
containing ibuprofen but no diluent. It was observed that the bioavailability of ibuprofen
improved to the same extent as with the same oral capsules and ibuprofen suppositories
(Ojantakanen et al. 1990; Eerikäinen et al. 1994). The bioavailability of the non-dipped capsules
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compared with the dipped ones was about 87%. Training alone improved the reproducibility of
ibuprofen absorption by approximately 35%. Further, the use of a glidant facilitated the
administration, increased the amount of drug absorbed and decreased the variations in AUC and
Cmax (I, Fig. 4., Table III). After this positive finding the subjects in the extension studies
practised the administration beforehand and used liquid paraffin to facilitate the application,
thereby improving the compliance.
Next, a bioavailability test was carried out in order to compare oral (plain ibuprofen) and rectal
routes (lactose-based capsules) for the administration of ibuprofen in hard gelatin capsules. In
this phase an additional aim was to investigate whether it is possible to modify the release of
ibuprofen with hydrophilic polymer (HPMC K15M). HPMC K15 M was chosen because it was
found to be an ideal polymer for sustaining the oral absorption of ibuprofen from hard gelatin
capsules (Ojantakanen 1993). 
The mean relative bioavailability of the rectal route with eight subjects was 99% (90% CI
0.81-1.18) compared with oral administration. The conclusion was that the bioavailabilty of
ibuprofen was not dependent on the two administration routes studied (which had the same
bioavailabilities) but rather on the diluents in the capsules. This means that these routes could be
considered bioquivalent to ibuprofen. This was also recently confirmed with ibuprofen HPMC
capsules studied in our laboratory by Honkanen (2001), where AUC0-24h values for rectal
administration were of the same magnitude or even higher than after oral drug administration. 
However, it was seen that there was a typical time lag of 0.5 to 1 hour at the beginning of the
rectal absorption phase, which was seen also in other pharmacokinetic parameters (I, Table IV),  
indicating a lower rectal absorption rate of ibuprofen. This was probably due to the longer
disintegration time of the capsule and subsequent dissolution of the ibuprofen. Hagenlocher et al.
(1987) have reported that the hard gelatin capsule is only a fast-dissolving drug container in the  
rectum and has no effect on the absorption characteristics of the drug. On the other hand, Eller
et al. (1989) reported that the absorption of rectally administered ibuprofen from solution was,
even though it was relatively well absorbed in healthy volunteers, still slower than after oral
administration. Interestingly, in three subjects the kinetics of absorption switched from first
order to zero order in Eller`s study. This may be due to the large dose and limited surface area,  
thus saturating the ability of the rectal membranes to allow ibuprofen to pass through. These
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might be, among the other things like lag-time, the main reasons for the slightly more prolonged
release of ibuprofen in rectal administration compared with peroral administration.
When HPMC K15M polymer was used in the capsules as a diluent, the absorption of ibuprofen
was clearly lower and the bioavailability was 68% of that for lactose-based capsules.  The
formulation behaved like a prolonged-release product, although the bioavailability was reduced
too much for it to be acceptable. Nevertheless, this convinced our study group to investigate in
more detail the possibility of developing a slow- or prolonged-release formulation of hard gelatin
capsules for rectal administration.    
4.2.2.  Development of slow- or prolonged-release formulations using ibuprofen as a model drug
(II)
The first part of the study showed that hard gelatin capsules are of value as a rectal dosage form
in man. However, proper attention must be paid to training in the application technicue, and the
use of a glidant is also important. Another important observation was that it is possible to
control the absorption rate and thereafter the extent of the bioavailability of ibuprofen by using
different diluents in hard gelatin capsules for rectal administration. This is contrary to the results
for the different oral capsule formulations studied earlier in our laboratory (Ojantakanen et al.
1990 and 1993, Hannula et al. 1991). Then it was observed that the diluents used in peroral
capsules had no effect on the extent of the bioavailability of ibuprofen, but only on the
absorption rate of ibuprofen. This phenomen is obviously due to the extraordinary absorption
site in the rectum compared with the other parts of the gastrointestinal tract.
4.2.2.1. Hydroxypropyl methylcellulose-based capsules (II)
Ojantakanen and Smal studied in our laboratory the possibility of formulating the prolonged-
release hard gelatin capsule preparations for oral administration in man (Ojantakanen et al. 1993)
and dogs (Smal et al. 1994) using different HPMC-grades as excipients. In this section we
investigated whether it is possible to produce an adequate prolonged-release ibuprofen
formulation for rectal administration using HPMC K100 and K4M as diluents in the capsules.
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Because of the findings of our previous studies with HPMC K15M (I), lower viscosity grades of
HPMC were chosen as excipients in the capsule formulations in order to control the release of
ibuprofen. Testing showed that there were no substantial differences in bioavailability between
these two HPMC-viscosity grades (II, Fig 2., 3.). It was noticed when comparing with
lactose-based capsules, that absoption phase was prolongened. The bioavailability of the K100
capsules was 0.97 (90% CI 0.79-1.14) and 0.83 for the K4M capsules (90 % CI 0.65-1.00). On  
the basis of bioavailability tests and individual variations (II, Fig. 3.), it can be said that the K100
capsules behaved acceptably as prolonged-release capsules and were bioequivalent to the
reference capsules. However, no statistical differences were found between the pharmacokinetic
parameters of these two lower HPMC-grades. The behaviour of the absorption curves was
roughly similar to the corresponding oral formulations in the study of Ojantakanen et al. (1993),
but at a slightly lower degree  In the earlier study (I), it was discovered that the bioavailibility of
HPMC K15M-based capsules was only 50% compared with the reference capsules (I). 
A recent study in our laboratory (Honkanen et al. 2001) concerning the differences between two
different capsule shells, gelatine and HPMC, showed that there were no statistically significant
(p>0.05) differences between the capsules. In addition, changing the viscosity grade of the  
HPMC diluent did not alter the biopharmaceutical characteristics of the rectal formulations. This
means that the dissolution test did not predict in vivo behaviour of the capsules when a rectal
dosage form was used, although good in vitro/in vivo correlation existed when the oral route was
used. However, on the basis of the results reported in this thesis it can be assumed that with
certain reservations the lower HPMC grades can be used to modify the release of ibuprofen in
rectal hard gelatin capsules in preference to the higher HPMC grades. The in vitro/in vivo
correlation was not satisfactory.
4.2.2.2. Polycarbophil-based capsules (II)
It has been reported that the rectal administration of ibuprofen with polyacrylic acid gel base has
been shown to be an effective method of administration (Hirano et al. 1980). Polyacrylic acid gel
base, a carboxyvinyl polymer, can be adjusted to a suitable pH and viscosity, and unpleasantness
during rectal administration is minimal (Morimoto et al. 1980). Concequently, when flurbiprofen,
ketoprofen and indomethacin gel preparations with a polyacrylic acid aqueous gel base were
administered to rats, the control of plasma concentration against time was relatively easy.
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Furthermore, this gel base was effective in the rectal administration of polypeptides such as
insulin and calcitonin. Also, gel preparations were highly useful as preparations administered
rectally with reduced side-effects and prolonged action. (Morimoto et al. 1983, Kazuhiro
Morimoto 1987.).
Hydrophilic polymers that bind to the gastric mucin or epithelial cell surface might be useful in
drug delivery for the purposes of retaining a dosage form in the gastrointestinal tract and
increasing the intimacy and duration of contact of the drug with the absorbing membrane.
Polycarbophil has previouly been shown to have such bioadhesive properties in the rat stomach
and small intestine. However, it has been reported that although covalent binding of polymers to
the mucin epithelial surface is a possible strategy for bioadhesive dosage forms, the desirability of
this approach is reduced by concern over potential toxicity and the difficulties involved in
preparing suitable dosage forms. Thus, polymers that adhere through electrostatic interactions,
dispersion forces and other non-covalent interactions are preferred for drug delivery purposes
(Longer et al. 1985).
The effect of amount of polycarbophil on the bioavailability of ibuprofen was studied (II). The
lactose to polycarbophil ratio in the capsules varied. Figure 4. (II) shows that with the capsules
which contained only polycarbophil as a diluent (100%) no plasma levels were detected. With
the capsule formulation containing 15% of polycarbophil the bioavailability was 35% (CI 90%).
Further, when the polycarbophil to lactose ratio was only 5:95, the bioavailability of the hard
gelatin capsules increased to 98% (90% CI 0.71-1.25). This formulation best fulfilled the
requirements for a prolonged-release formulation also in respect of the different
pharmacokinetic parameters (Cmax, tmax, MRT, Cmax/AUC). So when the amount of polycarbophil
was decreased and the proportion of lactose raised, the bioavailability of ibuprofen increased.
Further, it was considered that by clarifying the in vitro/in vivo characteristics of the polymers and
adjusting their amounts in the capsules, it is possible to produce prolonged-release formulations
for rectal administration when ibuprofen is used as the model drug. However, the in vitro
behaviour of the capsules gave a relatively weak prediction of the rectal absorption of ibuprofen
in man.
These findings concerning the dose adjustment of polycarbophil are in agreement with findings
with polyethylene suppositories containing polycarbophil as gel-forming polymer and
indomethacin as the drug (Hosny and Al-Angary 1995). They reported that higher
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concentrations of polycarbophil (5 to 8%), improved the sustaining action of the polycarbophil
but decreased blood levels and bioavailability, whereas lower concentrations (0 to 5%) improved
blood levels and bioavailability, but did not significantly improve the sustaining effect. They
concluded that the major thing in the formulation of suppositories is to use the optimum
concentration of polycarbophil, which achieves an improvement in blood levels, sustaining
action and bioavailability.  
4.2.3. Effect of sodium phosphates (III)
It is typical of rectal administration that there is a time lag of 0.5 to 1 h at the commencement of
absorption phase compared with oral administration. This is also most evident in the
administration of hard gelatin capsules. There are several reasons for the rectal time lag: e.g. lack
of buffer capasity and limited amount of fluids in the rectum (Newton 1987). It was also assumed
that the rate-limiting step in the absorption process in the rectum would be the dissolution of the
drug. Therefore the aim of this part of the study was to investigate whether it is possible to
increase the dissolution rate of ibuprofen by adding small amounts of sodium phosphates as
buffering additives in the capsules. Several studies have been reported on the possibility of
facilitating the liberation and absorption of a drug using pH-adjusting agents as additives in
suppositories (Takubo et al. 1973, 129; Moolenaar et al. 1984). These mechanisms can be
categorized as increasing the dissolution rate of the drug or the proportion of the undissociated
form of the drug. An explanation for the favourable rectal absorption of codeine base (pKa=8.1)
from an alkalized suppository was that most of the drug was in the non-ionized form thus
resulting in a favourable driving force for absorption (Moolenaar et al. 1983.)
Three different amounts of the adjuvants (0, 30 or 50 mg per 400 mg of ibuprofen) were
administered in lactose-based capsules (III, Table I) to volunteers. It was noticed that time lag at
the commencement of the absorption phase was diminished by approx. 12-18 minutes with
phosphate capsules. The decrease was greater with the formulation containing 50 mg of
phosphates. Also the bioavailability of the ibuprofen was slightly increased in vivo when the
phosphates were used in the capsules (III, Fig. 2.-3.). The absorption rate and, evidently, the
dissolution of ibuprofen was improved with the phosphate capsules (compared with the  
reference capsules) as described by the pharmacokinetic parameters: tmax (4.3 to 3.3-3.1 h),
Cmax/AUC (0.18 to 0.21-0.23) and MRT (4 to 3.4-3.5 h). The bioavailability of the 30 mg
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phosphate formulation was 1.19 (90% CI 0.90-1.41) compared with the reference capsules. It
was interesting that the bioavailability of the formulation containing 50 mg of phosphates was
95% (90% CI 0.67-1.23). However there were no statistically significant differencies between the
AUC values. The phosphates had no diminishing effect on individual variations. 
The in vivo results showed that the bioavailability was highest with the formulation containing 30
mg of phosphates. That result differed from the in vitro results. Thereafter it was considered that
part of the ibuprofen must be in a molecular form in order to be absorbed from the rectum to
the blood circulation. The unionized form of ibuprofen was probably diminished considerably  
more in the formulation containing 50 mg of phosphates and therefore the portion of ibuprofen  
absorbed was reduced (III, Fig. 2. and Table II). However, it was concluded that the primary
mechanism was an increase in the dissolution rate. This caused a decrease in the lag time and  
also might be dued to an improvement in the bioavailability of ibuprofen when 30 mg of sodium
phosphates were used as additives in the capsules. These observations concerning the
dissociation reactions of the capsule diluents are in agreement with the findings of Hannula et al.
(1991). 
4.2.4. Number of capsules (III)
In our earlier studies reported in this thesis the drug dose of 400 mg was administered in two
0-size capsules of 200 mg. Now the aim was to investigate if there is any difference in the
bioavailability when ibuprofen is administered either in one larger 00-size capsule (0.95 ml) or in
two smaller ones (0.50 ml). The old comprehension exists that the main thing in drug therapy is
the amount of drug in a single-dose. Other factors, like the number of dosage forms given at the
time, are less significant. This was considered to be of special importance in rectal
administration, because of the challenging absorption circumstances in the rectum. Schoonen et
al. (1979) stated that as far as slowly dissolving drugs are concerned in the fatty suppository
vehicle, increasing the drug concentration in the vehicle or enlarging the volume of the vehicle
chosen may influence the rectal absorption rate in different ways.
On the basis of bioavailability studies, it was seen that the bioavailability of ibuprofen was 25 %
greater after administration of two smaller capsules (III, Fig. 4. and 5., p<0.05). No statistically
significant differences were obtained in the pharmacokinetic parameters describing the
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absorption phase: Cmax, MRT and tmax values (Table III). The individual variations were slightly
greater after the administration of one bigger 00-size capsule than after administration of two
smaller capsules. 
This finding with hard gelatin capsules is in agreement with recent results with paracetamol
suppositories (Närvänen et al. 1998). Närvänen et al. found that a greater total mass of
suppositories, two 500 mg suppositories weighting 4,06 g, leads to improved spreading of the
melting mass in the rectum compared with one suppository (2,90 g). In addition, using two
separate suppositories or, analogically, hard gelatin capsules instead of one means that the
second dosage form pushes the first one deeper into the rectum so that the absorption area
increases.   
This finding might have some clinical importance, for example when using drugs with a narrow
therapeutic window. However, most of the subjects preferred the administration of one 00-size
capsule, because the application was simpler. Better compliance constituted a more important
argument, with further studies indicated particularly because of the comparatively unfamiliar
manner of administration. 
4.2.5. Comparison to commercial ibuprofen products (III) 
The last question considered in Study III, was the relative bioavailability of the hard gelatin
capsule formulation containing 30 mg of sodium phosphates versus a commercial suppository
(BuranaR) or a soft gelatin capsule (Burana-CapsR) administered rectally. In this case, the hard
gelatin capsules were pre-coated with hard fat (Witepsol W45) instead of being dipped into liquid
paraffin just prior to administration (III, IV). The melting point of the hard fat was 35 oC, and it
melted almost instantly after inserting the capsules into the dissolution vessel. Thus, the coating
did not affect the release of the ibuprofen. The capsule size 00 (0.95 ml) was chosen for the
study because of the easier application and better compliance. 
The dose corrections were made after the bioavailability test by simple calculations in order to
compare the results between the products. The bioavailability of the commercial suppository was
99% (90% CI 0.78-1.21) compared with the hard gelatin capsules. The bioavailability of rectally
administered soft gelatin capsules was 87% (90% CI 0.68-1.06) compared with the hard gelatin
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capsules as reference. For the hard gelatin capsules the tmax-value was 2.6 hours, while for the
soft capsules it was only 1.4 hours (III, Table IV.). The mean peak plasma levels of the
formulations were about the same, varying between 27.1 mg/l for the suppository, 27.1 for the
soft gelatin capsules and 27.8 for the hard gelatin capsules. These levels are in agreement with
the reports concerning oral commercial ibuprofen products: 23.3 and 30 mg/l for tablets
(Karttunen et al. 1990) and 31.4 mg/l for capsules (Gillespie et al. 1982). 
The time lag was absent at the commencement of concentration time curves for the soft gelatin
capsules, the reason for this was evidently that the ibuprofen was dissolved in the capsule liquid.
On the basis of the absorption (Figs. 6. and 7.), it can be also stated that there was no visible
time lag for the suppository product either. This was probably due to the formulatory factors of
the product  The bioavalability test showed that the precoated hard gelatin capsule formulation
was nearly bioequivalent to the commercial suppositories. Furthermore, the bioavailability of the
hard gelatin capsules was higher compared with the commercial soft gelatin capsules. From this
point of view the hard gelatin capsules once again proved to be a worthy rectal dosage form for
the administration of ibuprofen in man.
4.2.6. Development of modified-release formulations using metoclopramide hydrochloride as a
model drug (IV)
The previous studies in this thesis have shown that ibuprofen can be adequately administered
rectally in hard gelatin capsules (I, II, III). However, there have existed a clear time lag at the
beginning of the absorption curve in the bioavalability studies. Further, it was possible to shorten
this delaying phenomen by using small amounts of buffering additives in the capsules (III). It
was also shown that it is possible to prepare an adequate prolonged-release formulation using
hydrophilic polymers as diluents in rectally administered hard gelatin capsules (II). The main aim
of the final phase (IV) of the thesis was to clarify what happens if an acidic drug, ibuprofen, with
spraringly water-soluble characteristics is replaced with a freely water-soluble hydrochloride of a
basic drug, metoclopramide hydrochloride. The more specific aim was to determine whether it is
possible to develop both immediate-release and slow-or prolonged-release rectal formulation
from hard gelatin capsules containing metoclopramide hydrochloride as the active ingredient. A
commercial suppository was used as a reference product.  The study formulations are presented
in Table I (IV).
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4.2.6.1. Development of an immediate-release formulation
The mean bioavailability of metoclopramide for the hard gelatin capsules was 0.93 (90% CI
0.78-1.07). Thus the normal criterion for bioequivalence, 0.80-1.25,  was not fulfilled. There were
also clear time lags of 0.5 to 1.5 hours with hard gelatin capsules, this was not obtained with the
metoclopramide suppositories. Due to the lag, a mean transition of 1.5 hour in tmax values existed
between the two products (Table III). The tmax value, however, was slightly lower for the
metoclopramide capsules compared with the ibuprofen capsules containing 30 mg of phosphates
(III). The reason for this was evidently the rapid dissolution of the freely water-soluble salt form
of the drug. Hermann reported that in passive absorption processes it is necessary for a drug to
reach rapidly a high concentration in the rectal mucous membrane compartment. This is
obviously the reason why, for instance, certain salts of organic acids which are fairly soluble in
water are absorbed faster than their undissociated free acids. Once again, the time lag is
presumably due to several factors in the rectum: slower disintegration of capsule shell, liberation
and dissolution of the drug from the powder bed and subsequent spreading characteristics in an
absorption environment containing only a couple ml of fluid and covering a relatively small area.
Comparing the absorption rate of metoclopramide from the hard gelatin capsules with the
reference product by the pharmacokinetic parameters MRT and Cmax/AUC which describe the
absorption rate without time lag, there were no real differences. (IV, Table III, Fig. 2.). The
interindividual variation was greater with the hard gelatin capsules. The Cmax values of these two
formulations were similar (approx. 50 ng/ml) and also the AUC values were about the same.
Thus it could be suspected that the acceptable confidence interval for bioavailability might be
reached with a greater number of subjects.
The peak drug concentrations in plasma of this study correspond to the findings of Block et al.
(1981); where Cmax values were approximately 60 ng/ml wfor suppositories (dose 40 mg), 70
ng/ml for tablets (dose 26.7 mg) and 65 ng/ml for oral drops (dose 26.7 mg). However,
compared with our study, their AUC values were slightly higher for the oral formulations, but
lower for the suppositories. In Block`s study the rectal bioavailability of the metoclopramide
hydrochloride in suppository was slightly lower (53 %) than for the different oral dosage forms
(76-79%) compared with i.v. administration. The study showed that the rectal absorption was
incomplete, although several reports indicate also variable oral bioavailabilities (Bateman et al.
1979 and 1980). Block et al. concluded that, in order to achieve a similar therapeutic effect, a
higher dose is required for rectal than for oral application. On the contrary, Vergin et al. (1990)
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reported a bioavailability of 70 % for metoclopramide suppositories, thus corresponding closely
with that following oral administration of immediate-release tablet formulations (Harrington et al.
1983, Ross-Lee et al. 1981, Bateman 1983, Vergin et al. 1983, Berner et al. 1984, Block et al. 1981).
The reduction in the amount of metoclopramide available to the systemic circulation after rectal
administration is believed to be due the first-pass metabolism rather than poor absorption when
compared with intravenous total plasma clearance: this would be analogous to findings following
oral application (Vergin et al. 1990).  Thus Block`s conclusion that in rectal administration of
metoclopramide hydrochloride a higher dose of drug is required for a similar therapeutic effect
than with oral administration, is slightly contradictory.
4.2.6.2. Development of slow- or prolonged-release formulation
Metoclopramide as a high-clearance drug causes considerable interindividual variation after oral
medication (Ross-Lee et al. 1981, Bateman et al. 1979, Bateman 1983). It is, however,
predominantly absorbed throughout the gastrointestinal tract and would therefore give an
opportunity for the develoment of new rectal dosage forms (Vergin et al. 1990). The
development of retard forms of metoclopramide could also be important due to the necessity of
constant blood levels (Bateman et al. 1979). 
In order to obtain a slow- or prolonged-release product, a formulation with the 5% replacement
of lactose with polycarbophil was prepared analogously with the studies on ibuprofen. The
absorption curves showed that the polycarbophil-based formulation clearly sustained the
absorption of metoclopramide (IV, Fig. 2.). This was also evident when considering the
pharmacokinetic parameters reflecting the absorption rate, like tmax, MRT and Cmax/AUC; e.g.
transition of tmax values was over 2.5 hours compared with the lactose-based capsules. Also the
half-life of the terminal elimination phase (t1/2) was 1.5 hour longer than fot the other two  
products, thus indicating that polycarbophil-based capsules behaved as a true prolonged-release
formulation, not only as a slow-release product. However, there was a clear increase of the mean
time lag from 0.75 to 1.5 hour, which can be considered a negative point. This fact, however, is
probably not of major clinical significance in long-term drug therapy. Once again it was seen that
the in vitro results did not predict adequately the in vivo behaviour of the rectally administered
hard gelatin capsules. This was also probably due to the high-clerance character of  
metoclopramide, not just the rectal route. There are several studies reporting difficulties in
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finding a dissolution procedure that would correlate with the in vivo data with ibuprofen (Dash et
al. 1988, Vidgren et al. 1991). The biphasic dissolution character of polycarbophil-based
metoclopramide capsules was not seen in the in vivo absorption curves (IV, Fig. 2). It was seen
that polycarbophil can be used as a suitable polymer in an adjusted ratio in hard gelatin capsules
to control the release of metoclopramide hydrochloride.
Polycarbophil-based and lactose capsules containing metoclopramide hydrochloride were
bioquivalents in respect of the AUC values (1.00; 90%  CI 0.86-1.18). The mean bioavailability
was 0.94 (90% CI 0.78-1.08) compared with the reference suppository. When ibuprofen was
used as the model drug, the bioavailability of suppository was 0.99 (CI 0.78-1.21) compared with
the hard gelatin capsules. Although there are clear differences in solubility between these two
model drugs, the findings were about the same: there is a clear lag time at the commencement of
drug absorption with hard gelatin capsules, it is possible to modify the release of these drugs
with different solubility characteristics by using different additives in the capsules and the
absorption profiles of the model drugs are similar (tlag,  tmax). It can thus be concluded that the
solubility of the model drug is not so dominating in the rectal absorption process with hard
gelatin capsules. The mean bioavailability is not dependent on the administration route, while the
peak drug levels in plasma and the areas under the concentration-time curves corresponded to
the studies on oral ibuprofen and metoclopramide formulations. The success of rectal
administration using hard gelatin capsules proved to depend entirely on biopharmaceutical
factors including, for example, proper administration technique, choice of adequate drug,
employment of suitable excipients and adjustment of their amounts together with other
formulatory factors.   
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5. CONCLUSIONS
1. In rectally administered hard gelatin capsules, compounds with different           
                  biopharmaceutical characteristics can be administered adequately. Hard gelatin     
        capsules are of value as a rectal dosage form and offer a simple and effective
 means of drug therapy. However, attention must be paid to the right
 administration technique, including training in application. 
  
2. It is possible to modify the drug release from rectally administered hard gelatin     
     capsules using suitable pharmaceutical excipients and adjusting their amounts in   
       the capsules. In this study, adequate immediate-release and prolonged-release        
          formulations were obtained using ibuprofen and metoclopramide as model
 drugs.  
3. The solubility of the drug in the rectum is an essential factor for it to dissolve in   
                   the rectal fluid and to permeate through the mucosal barriers into the systemic
         blood circulation. However, the solubility is not so dominating, the formulatory    
         factors of the dosage form also proved to be of particular importance in the         
     absorption of the sparingly water-soluble ibuprofen and freely water-soluble
 metoclopramide hydrochloride.
4. The bioavailability of ibuprofen and metoclopramide hydrochloride in rectal hard
              gelatin capsules can be kept comparable with that of peroral dosage forms. So      
     the rectal administration route with hard gelatin capsules is not merely an              
                    alternative, but also a prime choice in certain clinical situations. However,         
a clear time lag of 0.5 to 1.5 hour was noticed at the commencement of drug        
              absorption; this normally causes a slightly slower absorption phase in the
administration of hard gelatin capsules. 
5.     It is known that a poor in vitro/ in vivo correlation is a problematic issue in rectal    
                      administration. This was also confirmed with the hard gelatin capsules. In vitro       
    studies are not enough in the development of drug formulations, but can offer      
 essential supportive data.
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